Mitochondrial Metabolism and Hepatic Complications of Obesity

Prospective Physiopathology Study of the Links Between Mitochondrial Dynamics and Fatty Liver Disease During Obesity

Status

Withdrawn

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03302481

Acronym

DMSO

Enrollment

Registered

2017-10-05

Start date

2017-01-01

Completion date

2017-01-01

Last updated

2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity surgery, liver, mitochondria, steatosis

Brief summary

The study aims to characterize mitochondrial metabolism in the liver of obesity surgery patients and to study its relationships with hepatic steatosis, inflammation, and fibrosis.

Detailed description

The study aims to characterize mitochondrial metabolism in the liver of obesity surgery patients and to study its relationships with hepatic steatosis, inflammation, and fibrosis. The protocols involves a per-operative hepatic needle biopsy for mitochondria characterization and histological scoring of steatosis, inflammation, and fibrosis

Interventions

OTHERliver biopsy

the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Intervention model description

patients with obesity surgery with a laparoscopic approach scheduled in the department of digestive surgery of the CHU de Nantes

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adult men and women * affiliated to a social security * candidate for laparoscopic obesity surgery

Exclusion criteria

* Excessive alcohol consumption:\> 20 g / day (woman),\> 30 g / day (male) * Chronic viral hepatitis B or C * Genetic hemochromatosis * Taking the following drugs for at least 3 months up to 6 months before the scheduled date of obesity surgery: systemic corticosteroids, amiodarone, methotrexate * Wilson's disease * autoimmune hepatitis * alpha 1-antitrypsin deficiency * abetalipoproteinemia * Contraindications to liver biopsy

Design outcomes

Primary

Measure	Time frame
Association between nonalcoholic steato-hepatitis and mitochondria morphological markers	Until 6 month

Contacts

PRINCIPAL_INVESTIGATORDavid JACOBI, Dr

Nantes University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026